New Scoring System Defines Hepatocellular Carcinoma Patients Who Achieve Most Benefit From TACE

Data from a number of clinical trials presented at the International Liver Congress™ 2013 shed new light on the use of TACE and SIRT in the treatment of hepatocellular carcinoma (HCC). Transarterial chemoembolization (TACE) is a technique in which small particles designed to block blood vessels mixed or coated with chemotherapeutic drugs are injected directly into an artery supplying the tumour; it has become a standard treatment in selected patients with HCC. New data has identified a scoring system which defines those HCC patients who achieve the most benefit from TACE... via Health News from Medical News Today Read More Here..